1Wilkinson, G. R., Drug Metabolism and Variability among Patients in Drug Response[J]. NEJM, 2005, 352:2211-2221
2Evans WE, Mcleod HL. Pharmacogenomic-drug diposition, drug target, and side effects[J]. N Engl J Med, 2003, 248(6):538
3Westphal K, Weinbrenner A. Oral biavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoportein [J]. Clin Pharamacol Ther,2000, 68:6-12
4Greiner B, Eichelbaum M, Fritz P et al,The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin[J]. J Clininvest ,1999, 104(2):147-53
5Jin M, Shimada T, Shintani M, et al.Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine [J]. Drug Metab Pharmacokinet,2005, 20(5):324-30
6Benet LZ, Lzumi T, Zhang Y et al. Intestinal MDR. transport proteins and p-450 enzymes as barriers to oral drug delivery[J]. J Control Release, 1999, 62(1-2):25-31
7Thummel KE, Wilkinson GR. In vitro and in vivo interactions involving human CYP3A [J]. Annu Key Pharmacol Toxicol,1998, 38:389-430
8Levy RH, Thummel KE, Trager WE, et al. Metabolic drug interactiom[M].Philadelphia: Lippincott Williams & Wilkins,2000
